BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) of -$8.00 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-07-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecrease · last filed 2012-07-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-06-30 was -$8.00M, a 153.33% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$9.00M, a 181.82% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-12-31 was -$7.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$23.00M, a 176.67% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2011 was -$4.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2010 was -$3.00M, a 133.33% decline from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2009 was $9.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2008 was -$3.00M, a 112.50% decline from fiscal 2007.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 6 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|---|
| 2012-06-30 | -$8.00M 10-Q · filed 2012-07-25 | -$17.00M 10-Q · filed 2012-07-25 | -$24.00M derived: sum of 3 quarters · filed 2012-07-25 | -$47.00M derived: sum of 4 quarters · filed 2012-07-25 | |
| 2012-03-31 | -$9.00M 10-Q · filed 2012-04-26 | -$16.00M derived: sum of 2 quarters · filed 2012-04-26 | -$39.00M derived: sum of 3 quarters · filed 2012-04-26 | -$24.00M derived: sum of 4 quarters · filed 2012-07-25 | |
| 2011-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$30.00M derived: sum of 2 quarters · filed 2012-02-17 | -$15.00M derived: sum of 3 quarters · filed 2012-07-25 | -$4.00M 10-K · filed 2012-02-17 | |
| 2011-09-30 | -$23.00M 10-Q · filed 2011-10-27 | -$8.00M derived: sum of 2 quarters · filed 2012-07-25 | $3.00M 10-Q · filed 2011-10-27 | ||
| 2011-06-30 | $15.00M 10-Q · filed 2012-07-25 | $26.00M 10-Q · filed 2012-07-25 | |||
| 2011-03-31 | $11.00M 10-Q · filed 2012-04-26 | ||||
| 2010-12-31 | -$3.00M 10-K · filed 2012-02-17 | ||||
| 2010-09-30 | $30.00M 10-Q · filed 2011-10-27 | $13.00M derived: sum of 2 quarters · filed 2011-10-27 | $0.00 derived: sum of 3 quarters · filed 2011-10-27 | -$9.00M derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-06-30 | -$17.00M 10-Q · filed 2011-07-28 | -$30.00M 10-Q · filed 2011-07-28 | -$39.00M derived: sum of 3 quarters · filed 2012-02-17 | -$19.00M derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-03-31 | -$13.00M 10-Q · filed 2011-04-28 | -$22.00M derived: sum of 2 quarters · filed 2012-02-17 | -$2.00M derived: sum of 3 quarters · filed 2012-02-17 | $13.00M derived: sum of 4 quarters · filed 2012-02-17 | |
| 2009-12-31 | -$9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $11.00M derived: sum of 2 quarters · filed 2012-02-17 | $26.00M derived: sum of 3 quarters · filed 2012-02-17 | $9.00M 10-K · filed 2012-02-17 | |
| 2009-09-30 | $20.00M 10-Q · filed 2010-10-26 | $35.00M derived: sum of 2 quarters · filed 2010-10-26 | $18.00M 10-Q · filed 2010-10-26 | $12.00M derived: sum of 4 quarters · filed 2011-02-18 | |
| 2009-06-30 | $15.00M 10-Q · filed 2010-07-22 | -$2.00M 10-Q · filed 2010-07-22 | $2.00M 10-Q · filed 2009-07-23 | -$8.00M derived: sum of 3 quarters · filed 2011-02-18 | $14.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | -$17.00M 10-Q · filed 2010-04-29 | -$23.00M derived: sum of 2 quarters · filed 2011-02-18 | -$1.00M derived: sum of 3 quarters · filed 2011-02-18 | $15.00M derived: sum of 4 quarters · filed 2011-02-18 | |
| 2008-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $16.00M derived: sum of 2 quarters · filed 2011-02-18 | $32.00M derived: sum of 3 quarters · filed 2011-02-18 | -$3.00M 10-K · filed 2011-02-18 | |
| 2008-09-30 | $22.00M 10-Q · filed 2009-10-22 | $38.00M derived: sum of 2 quarters · filed 2009-10-22 | $3.00M 10-Q · filed 2009-10-22 | ||
| 2008-06-30 | $16.00M 10-Q · filed 2009-07-23 | $19.00M 10-Q · filed 2009-07-23 | |||
| 2007-12-31 | $24.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |